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May 20111456 Letters to the EditorRegarding “Prospective randomized trial comparing
endovenous laser ablation and surgery for treatment
of primary great saphenous varicose veins with a
2-year follow-up”
As authors of a systematic review on the treatment of
varicose veins, we closely scrutinized the recent publication by
Christenson et al1 for potential inclusion. Christenson et al
randomized the treatment of 200 limbs with primary varicose
veins to receive conventional surgery or endovenous laser abla-
tion.
The primary outcome measure was closure of the great
saphenous vein. Secondary outcome measures included general
health quality of life measures (Short Form 36) and disease-
specific measures (Aberdeen Varicose Vein Symptom Severity
Score and Venous Clinical Severity Score). Postoperative com-
plications, time to return to normal activity, and pain scores
(mean use of analgesics and a visual analog scale score) were
noted.
After contacting the corresponding author, we confirmed that
40 patients underwent treatment of bilateral varicose veins, al-
though this was not clear from the article itself. All patients with
bilateral varicose veins were treated on the same day. We also
confirmed that patient’s limbs were randomized, not the patients
themselves. In fact, eight patients underwent surgery on one limb
and laser treatment on the other on the same day.
Clear biases result from this methodology, especially regard-
ing the postoperative quality of life scores. The high proportion of
bilaterally treated patients also affects pain scores. Time to return
to work is also published, but limbs cannot return to work inde-
pendently of one another. Trials that randomize and analyze
results according to number of limbs rather than the number of
patients as the unit of analysis result in the standard error of the
treatment effect being much smaller than it should be.
The shortcomings in this trial mean that the results must be
taken with caution. Greater effort must be made in the future to
publish trial data with greater transparency, and future trialists
must heed the pitfall of randomizing patients’ limbs rather than the
patients themselves. Investigators must give further thought on
how to approach the problems of including, randomizing, and
Table. Outcome comparison between high ligation and st
ablation of primary great saphenous varicose veins at 2-yea
after exclusion of patients with bilateral treatment
Variables
Results presented in
HL/S n  100
limbs P
Limbs lost 1 .212
Limbs analyzed 99 .212
Primary end points
GSV absent/completely closed 99 1.0
GSV completely reopened 0 —
GSV partially reopened 0 —
GSV completely  partially
reopened or detectable 0 .051
Reflux 2 .050
Limbs with symptoms 1 .007
GSV, Great saphenous vein.
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The point raised by this reader is well taken, and we agree that
ome aspects of the postoperative quality of life might be affected by
hemethodology used.However, ruling out the 40 patients (58 limbs
n the surgical arm and 62 in the endovenous laser arm) who under-
ent bilateral treatment did not affect the overall results (Table). In
ddition, the Aberdeen Varicose Vein Symptom Severity Score and
enous Clinical Severity Score did not change, and there were no
ignificant changes in Short Form 36 scores when the bilaterally
reated patients were excluded from the analysis compared with when
heywere included and presented in our article. This does not rule out
ut at least attenuates the reader’s concern.
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ng (HL/S) and endovenous laser treatment (EVLT) for
llow-up comparing results as presented in the articlea and
rticle Results after exclusion of bilat treatment
VLT n  100
limbs
HL/S n  58
limbs/patients P
EVLT n  62
limbs/patients
5 0 .496 2
95 58 .496 60
88 58 1.0 54
2 0 — 2
5 0 — 4
7 0 .027 6
8 0 .013 7
9 0 .006 8
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